Encainide hydrochloride

Modify Date: 2024-01-16 19:18:24

Encainide hydrochloride Structure
Encainide hydrochloride structure
Common Name Encainide hydrochloride
CAS Number 66794-74-9 Molecular Weight 388.93100
Density 1.106g/cm3 Boiling Point 439.9ºC at 760mmHg
Molecular Formula C22H29ClN2O2 Melting Point N/A
MSDS Chinese USA Flash Point 219.8ºC
Symbol GHS06
GHS06
Signal Word Danger

 Use of Encainide hydrochloride


Encainide (MJ9067) hydrochloride is an antiarrhythmic drug with class IC activity. Encainide has the potential for life-threatening ventricular arrhythmias, symptomatic ventricular arrhythmias and supraventricular arrhythmias research[1].

 Names

Name encainide hydrochloride
Synonym More Synonyms

 Encainide hydrochloride Biological Activity

Description Encainide (MJ9067) hydrochloride is an antiarrhythmic drug with class IC activity. Encainide has the potential for life-threatening ventricular arrhythmias, symptomatic ventricular arrhythmias and supraventricular arrhythmias research[1].
Related Catalog
In Vivo Encainide hydrochloride (MJ9067 hydrochloride; 0.3, 0.9, 2.7 mg/kg; infusion of single doses) prolongs His-Purkinje conduction time (HV interval) and intra-ventricular conduction time (QRS duration) but has no effect on sinus nodal recovery time or AV nodal conduction, or on refractoriness of atrium, AV node, or ventricular myocardium or on QT interval[1].
References

[1]. R N Brogden, et al. Encainide. A review of its pharmacological properties and therapeutic efficacy. Drugs. 1987 Nov;34(5):519-38.

 Chemical & Physical Properties

Density 1.106g/cm3
Boiling Point 439.9ºC at 760mmHg
Molecular Formula C22H29ClN2O2
Molecular Weight 388.93100
Flash Point 219.8ºC
Exact Mass 388.19200
PSA 41.57000
LogP 5.17730
Storage condition 2-8°C

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
CV5521500
CHEMICAL NAME :
Benzamide, 4-methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)pheny l)-, monohydrochloride, (+-)-
CAS REGISTRY NUMBER :
66794-74-9
LAST UPDATED :
199604
DATA ITEMS CITED :
7
MOLECULAR FORMULA :
C22-H28-N2-O2.Cl-H
MOLECULAR WEIGHT :
388.98

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
57 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
86 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
16 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
43 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
17 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Primate - monkey
DOSE/DURATION :
8 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
5500 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NDADD8 New Drugs Annual: Cardiovascular Drugs. (New York, NY) V.1-2, 1983-84. For publisher information, see NCDREP. Volume(issue)/page/year: 1,93,1983

 Safety Information

Symbol GHS06
GHS06
Signal Word Danger
Hazard Statements H301-H315-H319-H335
Precautionary Statements P261-P301 + P310-P305 + P351 + P338
Personal Protective Equipment Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
Hazard Codes T
Risk Phrases 25-36/37/38
Safety Phrases 26-45
RIDADR UN 2811 6.1/PG 3
RTECS CV5521500

 Articles26

More Articles
Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents.

Clin. Pharm. 6(11) , 839-50, (1987)

The chemistry, electrophysiology, pharmacokinetics, clinical use and efficacy, adverse effects, drug interactions, and dosage of encainide hydrochloride and flecainide acetate are reviewed. Encainide ...

ST segment elevation induced by class IC antiarrhythmic agents: underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia.

J. Cardiovasc. Electrophysiol. 9(11) , 1167-72, (1998)

Three patients in whom Class IC sodium channel blockers induced ST segment elevation in leads V1 through V3 are described. The underlying electrophysiologic mechanism, implications for drug-induced pr...

Adherence and arrhythmic mortality in the cardiac arrhythmia suppression trial (CAST).

Ann. Epidemiol. 6(2) , 93-101, (1996)

Patient adherence to therapy is essential to assess treatment efficacy, particularly in clinical trials. Active treatment usually is expected to benefit patients. The healthy adherer effect, the assoc...

 Synonyms

(+-)-2'-(2-(1-Methyl-2-piperidyl)ethyl)-p-anisanilide monohydrochloride
4-methoxy-N-[2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl]benzamide,hydrochloride
Benzamide,4-methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)-,monohydrochloride,(+-)
Encainide hydrochloride
4-Methoxy-2'-(2-(1-methyl-2-piperidyl)ethyl)benzanilide hydrochloride
Encainide HCl
Encainide hydrochloride (USAN)
Enkaid